Analytical Data
-
基因名
CD22
- Application
-
别名
CD22；SIGLEC2；B-cell receptor CD22
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P20273
-
表达区间
22-685aa
-
氨基酸序列
SKWVFEHPETLYAWEGACVWIPCTYRALDGDLESFILFHNPEYNKNTSKF DGTRLYESTKDGKVPSEQKRVQFLGDKNKNCTLSIHPVHLNDSGQLGLRM ESKTEKWMERIHLNVSERPFPPHIQLPPEIQESQEVTLTCLLNFSCYGYP IQLQWLLEGVPMRQAAVTSTSLTIKSVFTRSELKFSPQWSHHGKIVTCQL QDADGKFLSNDTVQLNVKHTPKLEIKVTPSDAIVREGDSVTMTCEVSSSN PEYTTVSWLKDGTSLKKQNTFTLNLREVTKDQSGKYCCQVSNDVGPGRSE EVFLQVQYAPEPSTVQILHSPAVEGSQVEFLCMSLANPLPTNYTWYHNGK EMQGRTEEKVHIPKILPWHAGTYSCVAENILGTGQRGPGAELDVQYPPKK VTTVIQNPMPIREGDTVTLSCNYNSSNPSVTRYEWKPHGAWEEPSLGVLK IQNVGWDNTTIACAACNSWCSWASPVALNVQYAPRDVRVRKIKPLSEIHS GNSVSLQCDFSSSHPKEVQFFWEKNGRLLGKESQLNFDSISPEDAGSYSC WVNNSIGQTASKAWTLEVLYAPRRLRVSMSPGDQVMEGKSATLTCESDAN PPVSHYTWFDWNNQSLPYHSQKLRLEPVKVQHSGAYWCQGTNSVGKGRSP LSTLTVYYSPETIG
-
分子量
75 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CD22 is a transmembrane glycoprotein critically involved in the regulation of B-cell receptor (BCR) signaling, thereby playing a vital role in B-cell development, activation, and survival. As a member of the immunoglobulin superfamily, CD22 serves as a crucial negative regulator of B-cell activation, helping maintain immune homeostasis. Its dysregulation is associated with various B-cell malignancies and autoimmune diseases, making it an important target for therapeutic interventions. The study of CD22 recombinant proteins has gained traction due to their potential in understanding B-cell signaling pathways and developing novel immunotherapies. Furthermore, recombinant CD22 proteins can be utilized to generate specific antibodies or chimeric antigen receptor (CAR) T cells for targeted treatment of CD22-positive tumors, such as certain leukemias and lymphomas. Investigating the structural and functional aspects of CD22 through recombinant technologies not only enhances our comprehension of B-cell biology but also paves the way for innovative strategies in cancer immunotherapy and autoimmune disorder management. With the growing interest in engineered proteins and their therapeutic implications, research on CD22 recombinant proteins holds promise for advancing personalized medicine and improving patient outcomes in hematological malignancies.
